ANTIGIPERTENZIV DORI PREPARATLARIDAN SARTANLAR GURUHIGA MANSUB TELMISARTANNING GIPOTENZIV VA ORGANOPROTEKTORLIK XUSUSIYATLARI

##article.authors##

  • ABDURASULOVA Nargiza Olimovna
  • ERGASHOVA Madina Muxtorovna

##article.subject##:

Arterial hypertension (AH), arterial blood pressure (ABP), hypotensive agents, sartans, ARA, telmisartan

##article.abstract##

Arterial bosimning muntazam me’yordan balandligi arterial gipertenziya (AG) sindromi ko’rinishida yurak-qon tomir kasalliklari bilan bir qatorda boshqa kasalliklarda ham uchraydi. Jahon Sog’liqni Saqlash Tashkiloti (JSST) tahlillariga ko’ra 20 yoshdan oshgan aholining 27% da AG kuzatiladi. 2025 yilga kelib bu ko’rsatgich 29% ni tashkil etgan. O’zbekistonning 40-60 yosh oralig’idagi aholisida esa AG 30,4% hollarda kuzatilgan. Ushbu tadqiqotimizda Angiotenzin II retseptor antogonistlari (ARA) sinfiga mansub preparatlardan, asosan telmisartanning asosiy ta’sir mexanizmlari ko’rib chiqiladi.

Библиографические ссылки

Mehta JK, Kaur G, Buttar HS, et al. Role of the renin-angiotensin system in the pathophysiology of coronary heart disease and heart failure: Diagnostic biomarkers and therapy with drugs and natural products. Front Physiol. 2023

Bhardwaj G. How the antihypertensive losartan was discovered. Expert Opin Drug Discov. 2006

Baguet JP, Robitail S, Boyer L, et al. A meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure. Am J Cardiovasc Drugs. 2005

Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009

Wei J, Galaviz KI, Kowalski AJ, et al. Comparison of Cardiovascular Events Among Users of Different Classes of Antihypertension Medications: A Systematic Review and Network Meta-analysis. JAMA Netw Open. 2020

Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018.

Messerli FH, Bangalore S, Bavishi C, Rimoldi SF. Angiotensin- Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use? J Am Coll Cardiol. 2018

Конради А.О., Агеев Ф.Т., Галявич А.С., Карпов Ю.A., Кобалава Ж.Д., Котовская Ю.В., Недогода С.В., Недошивин А.О., Ткачева О.Н. Клиническое применение фиксированной комбинации телмисартана и индапамида для лечения артериальной гипертонии. Резолюция Совета Экспертов. Российский кардиологический журнал. 2025. (in Russ).

Rizaev A. Jhasur , Makhmonov S. Lutfulla , Gadaev G. Abdugaffor , Turakulov I. Rustam. Assessment of external factors involved in prediction of iron deficiency anemia associated with Helicobacter Pylori. Journal of Biomedicine and Practice. 2022, vol.7, issue 4, pp. 436-446

Rizaev , Zh ., & Yunuskhanova , K. (2021). Pathobiological interactions of rheumatoid arthritis and periodontal disease. Medicine and Innovation, 1(2), 37–40.

Mancia G, Kreutz R, Brunström M, et al. ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023.

Nurmamatovich E. O., Makhammatkulovich R. N., Shavkatovna S. S. MARKER TNF-308G/A IN PATIENTS WITH RELATIVE BLADDER CANCER //World Bulletin of Public Health. – 2023. – Т. 28. – С. 95-97.

Shavkatovna S. S., Makhammatkulovich R. N. FEATURES OF SARCOPENIA IN CANCER PATIENTS //EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE. – 2024. – Т. 4. – №. 8. – С. 286-292.

Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008.

Загрузки

##submissions.published##

2026-05-20